Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors
Open Access
- 31 October 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (21), 6888-6896
- https://doi.org/10.1158/1078-0432.ccr-11-1074
Abstract
Purpose: Bavituximab is a chimeric immunoglobulin G1 phosphatidylserine-targeting monoclonal antibody that triggers vascular disruption and enhances antitumor immune response. This phase I study assessed the safety and pharmacokinetics of bavituximab in patients with advanced solid tumors.This publication has 32 references indexed in Scilit:
- Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic AdenocarcinomaAmerican Journal of Clinical Oncology, 2011
- Increases in Quantitative D-Dimer Levels Correlate With Progressive Disease Better Than Circulating Tumor Cell Counts in Patients With Refractory Prostate CancerAmerican Journal of Clinical Pathology, 2010
- Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseasesNature Medicine, 2008
- Vascular Imaging of Solid Tumors in Rats with a Radioactive Arsenic-Labeled Antibody that Binds Exposed PhosphatidylserineClinical Cancer Research, 2008
- Radiation-Enhanced Vascular Targeting of Human Lung Cancers in Mice with a Monoclonal Antibody That Binds Anionic PhospholipidsClinical Cancer Research, 2007
- Management of Venous Thromboembolism in Patients With Primary and Metastatic Brain TumorsJournal of Clinical Oncology, 2006
- Pharmacokinetic profile of cetuximab (Erbitux™) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinomaEuropean Journal Of Cancer, 2005
- Regulation of transbilayer plasma membrane phospholipid asymmetryJournal of Lipid Research, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF.JCI Insight, 1998